Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 856 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... January 13, 2025 ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March March 14, 2025 Persistent Poverty Linked to Increased Risk of Dying from Cancer November 19, 2020 Phytochemicals and Antioxidants December 11, 2020 Load more HOT NEWS Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... That Cancer Conversation is back! How radiotherapy became a lifesaver – from X-rays to the proton... Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer
